Fig. 4
From: A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients
Survival curve: time until death by treatment group. In the group randomized to 100 μg IC43 without adjuvant, there was statistically significantly lower mortality versus placebo by day 28 (P = 0.0099, log-rank and Cox regression analysis) and significantly longer survival during the study versus placebo (P = 0.0196, Cox regression analysis). w/o without aluminum hydroxide adjuvant